electroCore, Inc. (ECOR): Price and Financial Metrics

electroCore, Inc. (ECOR): $0.36

-0.01 (-2.44%)

POWR Rating

Component Grades













ECOR Stock Summary

  • ECOR has a higher market value than only 8.41% of US stocks; more precisely, its current market capitalization is $24,840,750.
  • For ECOR, its debt to operating expenses ratio is greater than that reported by only 7.28% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.21 for ELECTROCORE INC; that's greater than it is for merely 13.81% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ELECTROCORE INC, a group of peers worth examining would be EKSO, XGN, SGHT, CXM, and PHUN.
  • ECOR's SEC filings can be seen here. And to visit ELECTROCORE INC's official web site, go to www.electrocore.com.

ECOR Valuation Summary

  • ECOR's price/earnings ratio is -1.1; this is 104.74% lower than that of the median Healthcare stock.
  • ECOR's EV/EBIT ratio has moved up 18 over the prior 54 months.

Below are key valuation metrics over time for ECOR.

Stock Date P/S P/B P/E EV/EBIT
ECOR 2022-11-25 3.1 1.0 -1.1 -0.1
ECOR 2022-11-23 2.8 1.0 -1.0 0.0
ECOR 2022-11-22 2.8 1.0 -1.0 0.0
ECOR 2022-11-21 3.3 1.1 -1.2 -0.2
ECOR 2022-11-18 3.2 1.1 -1.1 -0.1
ECOR 2022-11-17 3.1 1.1 -1.1 -0.1

ECOR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ECOR has a Quality Grade of D, ranking ahead of 7.18% of graded US stocks.
  • ECOR's asset turnover comes in at 0.134 -- ranking 150th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows ECOR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 0.575 -0.889
2021-03-31 0.121 0.545 -0.989
2020-12-31 0.113 0.503 -1.363
2020-09-30 0.102 0.596 -1.709
2020-06-30 0.085 0.537 -2.148
2020-03-31 0.069 0.522 -1.815

ECOR Price Target

For more insight on analysts targets of ECOR, see our ECOR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.60 Average Broker Recommendation 1.5 (Moderate Buy)

ECOR Stock Price Chart Interactive Chart >

Price chart for ECOR

ECOR Price/Volume Stats

Current price $0.36 52-week high $0.98
Prev. close $0.36 52-week low $0.20
Day low $0.35 Volume 300,500
Day high $0.39 Avg. volume 796,664
50-day MA $0.32 Dividend yield N/A
200-day MA $0.48 Market Cap 25.28M

electroCore, Inc. (ECOR) Company Bio

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is based in Basking Ridge, New Jersey.

ECOR Latest News Stream

Event/Time News Detail
Loading, please wait...

ECOR Latest Social Stream

Loading social stream, please wait...

View Full ECOR Social Stream

Latest ECOR News From Around the Web

Below are the latest news stories about ELECTROCORE INC that investors may wish to consider to help them evaluate ECOR as an investment opportunity.

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout Belgium and enables product recognition throughout the pharmaceutica

Yahoo | November 18, 2022

electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum.Canaccord Genuity MedTech and Diagnostics and Digital Health & Services ForumDate: Thursday, November 17, 2022Event: One-on-one meetings About electroCore, Inc.electroCore,

Yahoo | November 14, 2022

ECOR: Currency Pressures Nick OUS Revenues

By John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT Third Quarter 2022 Financial and Operational Results For the third quarter of 2022, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.0 million vs. $1.5 million in the prior year period. While year over year growth was up 33%, sales decelerated in the third quarter due to slower sequential trends in

Yahoo | November 4, 2022

electroCore Announces Third Quarter 2022 Financial Results

Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced third quarter 2022 financial results and provided an operational update. Third Quarter 2022 and Recent Highlights Posted revenue of approximately $2.0 million, representing an increase of approximately 33% ove

Yahoo | November 3, 2022

electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage, bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA cleared non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within select managed care health systems.

Yahoo | November 1, 2022

Read More 'ECOR' Stories Here

ECOR Price Returns

1-mo 9.09%
3-mo -29.47%
6-mo -37.06%
1-year -48.78%
3-year -79.07%
5-year N/A
YTD -38.20%
2021 -62.66%
2020 -1.89%
2019 -74.60%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6492 seconds.